Quarterly report pursuant to Section 13 or 15(d)

(Loss) Earnings per Share (Tables)

v3.23.1
(Loss) Earnings per Share (Tables)
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Earnings Per Share, Including Antidilutive Securities Excluded from Computation of Earnings Per Share
Basic and diluted (loss) earnings per share for the three months ended March 31, 2023 and 2022, respectively consisted of the following (in thousands, except per share data):
Three Months Ended
March 31,
2023 2022
Numerator (Basic and Diluted):
Net (loss) income $ (5,833) $ 32,783 
Change in value for stock settled consideration 18  (63)
Adjusted net (loss) income $ (5,815) $ 32,720 
Denominator:
Basic
Weighted average common shares issued and outstanding 39,211 39,721
Deduct: Unvested RSAs (1)
(11) (13)
Add: Fully vested DSUs (2)
— 281
Weighted average common shares outstanding 39,200 39,989
Basic (loss) earnings per common share $ (0.15) $ 0.82 
Diluted
Weighted average common shares outstanding from above 39,200 39,989
Add: Dilutive effect of RSUs, RSAs & ESPP(5)
— 396
Add: Contingently issuable shares(3)(5)
— 89
Weighted average common shares outstanding 39,200 40,474
Diluted (loss) earnings per common share $ (0.15) $ 0.81 
Antidilutive shares excluded from diluted earnings per common share(4)
1,608 778
(1)RSAs were issued and outstanding to the non-employee directors and have a one-year vesting term subject to service requirements. See Note 9 – “Stock-Based Compensation Plans” for additional information.
(2)Shares are included in weighted average common shares outstanding as the shares are fully vested but have not yet been delivered. See Note 9 – “Stock-Based Compensation Plans” for additional information.
(3)Relates to contingently issuable stock settled consideration.
(4)Primarily pertaining to RSU grants to the Company’s employees and independent contractors.
(5)Shares related to the Company's RSUs, RSAs, ESPP, and contingently issuable shares were excluded from the weighted average common shares outstanding for the quarter ended March 31, 2023 because inclusion of such shares would be antidilutive in a period of loss.